Mydecine Innovations Group Inc. Share Price NEO Exchange
Equities
MYCO
CA62849F2008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.175 CAD | +45.83% | +29.63% | -61.11% |
01/05 | Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding | CI |
23/02 | Mydecine Innovations Closes Partial Debt Settlement | MT |
Sales 2021 | 0.01 0.01 0.63 | Sales 2022 | - | Capitalization | 7.58M 10.31M 632M |
---|---|---|---|---|---|
Net income 2021 | -28M -38.09M -2.34B | Net income 2022 | -11M -14.96M -918M | EV / Sales 2021 | 5,24,95,60,605 x |
Net Debt 2021 | 3.01M 4.09M 251M | Net Debt 2022 | 153K 208K 12.78M | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.13
x | P/E ratio 2022 |
-0.44
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.04% |
1 day | +45.83% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Roscow
FOU | Founder | - | 27/13/27 |
Damon Michaels
FOU | Founder | - | 27/13/27 |
David Bartch
CEO | Chief Executive Officer | - | 22/18/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Bartch
CEO | Chief Executive Officer | - | 22/18/22 |
Damon Michaels
FOU | Founder | - | 27/13/27 |
Robert Roscow
FOU | Founder | - | 27/13/27 |
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- MYCOF Stock
- MYCO Stock